Search

Displaying results 3721 - 3730 of 8412 in total
  1. Drug

    Typhoid Vaccine Live

    go.drugbank.com/drugs/DB11050
    ApprovedInvestigational

    The vaccine prevents the development of typhoid fever, an acute, febrile enteric disease caused by *Salmonella typhi* by inducing a local immune response in the intestinal tract.

  2. Drug

    Oxyphenonium

    go.drugbank.com/drugs/DB00219
    Approved

    It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [PubChem]

  3. Drug

    Flavoxate

    go.drugbank.com/drugs/DB01148
    Approved

    A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear.

    Products: U-SPA
  4. Drug

    Dexchlorpheniramine

    go.drugbank.com/drugs/DB13679
    Investigational

    It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  5. Drug

    Azetukalner

    go.drugbank.com/drugs/DB21551
    Investigational

    Azetukalner is under investigation in clinical trial NCT05718817 (An Open-label Study of XEN1101 in Epilepsy). Azetukalner has a monoisotopic molecular weight of 368.23 Da.

  6. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. … Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 Inducers
  7. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system.

  8. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    MAXY-G34 is a pegylated variant of human granulocyte-colony stimulating factor (G-CSF). This variant contains multiple non-naturally occurring lysines that have been introduced into alpha helixes of wild type human G-CSF as PEGylation si...

  9. Drug

    Tesmilifene

    go.drugbank.com/drugs/DB04905
    Investigational

    Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  10. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757] … CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.